Fei et al. found that the addition of hydroxychloroquine to neoadjuvant chemotherapy in patients with PDA may improve the therapeutic response in SMAD4/DPC4-deficient patients. This evidence concerns the gene SMAD4 and Patent ductus arteriosus.